跳至主要内容
临床试验/NCT01612325
NCT01612325已完成2 期

Radioactive Holmium Microspheres for the Treatment of Patients With Unresectable Liver Metastases; a Single Center, Interventional, Non-randomized, Phase II (HEPAR II) Trial

UMC Utrecht2 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
UMC Utrecht
入组人数
56
试验地点
2
主要终点
Target lesions tumour response

研究概览

简要总结

Radioembolisation is a known method for the treatment of liver tumors and or livermetastases. Currently small beadlets called microspheres are used that are loaded with the beta radiation emitting Yttrium-90. Holmium-166 microspheres have different physical characteristics including good visualisation in gammacameras due to the gamma emission. Because of the higher specific activity higher radiation doses to the liver will be used compared to the standard Yttrium treatment. It is hypothesized that higher doses of irradiation have an improved antitumor effect.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Target lesions tumour response

时间窗: 3 month after treatment

After the administration of the Ho-166 microspheres the size of the target lesions in the liver will be determined using RECIST 1.1 criteria using CT scan

次要结局

  • Toxicity according CTC v 4 criteria(Clinical evaluation after 1,3,6,9,12,24,36,52 weeks)

研究者

发起方
UMC Utrecht
申办方类型
Other
责任方
Principal Investigator
主要研究者

B.A. Zonnenberg

principal investigator

UMC Utrecht

研究点 (2)

Loading locations...

相似试验

Radioactive Holmium Microspheres for the Treatment... | 临床试验